Authored & revised by Pulathi Senaratna(Founder & Senior Editor) · Updated 7 Nov 2026
✓ Clinically reviewed by Medipaedia Editorial Board on 7 Nov 2026mID 10049
⚡ At-a-Glance Clinical Summary Card
ICD-10: M32.9ICD-11: 4A40.0
⚡ High-Yield Clinical Summary
Systemic lupus erythematosus is a chronic multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production, and immune complex deposition leading to widespread tissue inflammation. Diagnosis is established via the 2019 EULAR/ACR classification criteria requiring an entry screening ANA titer of at least 1:80 alongside additive weighted clinical and immunologic domains. First-line therapy centers on universal hydroxychloroquine administration (≤5 mg/kg/day) coupled with photoprotection, supplemented by glucocorticoids for acute flares and targeted immunosuppression (such as mycophenolate mofetil or belimumab) for organ-threatening manifestations like lupus nephritis.
Universal Hydroxychloroquine (≤5 mg/kg/day for all patients unless contraindicated) + Photoprotection + Corticosteroids for flares + Mycophenolate mofetil / Cyclophosphamide / Belimumab / Rituximab for organ-threatening Lupus Nephritis
Systemic lupus erythematosus (EULAR/ACR criteria) is a chronic, multisystemic autoimmune inflammatory disease characterized by a profound breakdown of immunologic self-tolerance, the overproduction of diverse pathogenic autoantibodies, and circulating immune complex deposition across multiple organ systems1, 2. The clinical phenotype is exceptionally heterogeneous, ranging from mild mucocutaneous and musculoskeletal manifestations to life-threatening renal, neurological, and hematologic involvement3, 7. Affecting approximately 3.4 million individuals worldwide with a striking female predominance (roughly 9:1 ratio during childbearing years), the condition is driven by complex interactions among genetic susceptibility loci, environmental triggers such as ultraviolet light, and hormonal influences that dysregulate both innate and adaptive immune responses1, 4, 5, 7.
1. Etiology & Risk Factors
Genetic Susceptibility: Polygenic architecture involving over 100 susceptibility loci linked to immune regulation, Fc-gamma receptor clearance functions, toll-like receptor signaling, and the major histocompatibility complex (MHC), alongside rare monogenic complement pathway deficiencies (e.g., homozygous C1q, C2, or C4 defects)5, 7.
Hormonal & Endocrine Influences: Marked female predilection during reproductive years, compounded by disease flares triggered during pregnancy or exogenous estrogen exposure, reflecting estrogen receptor modulation on autoreactive lymphocytes4, 7.
Environmental Triggers: Ultraviolet (UV) radiation exposure inducing keratinocyte apoptosis and autoantigen surface blebbing, Epstein-Barr virus (EBV) primary or reactivated infection causing molecular mimicry and bystander lymphocyte activation, and exposure to specific xenobiotics or medications (e.g., drug-induced lupus from hydralazine, procainamide, or minocycline)5, 7.
Demographic & Socioeconomic Factors: Higher incidence, earlier age of onset, and significantly more aggressive disease courses observed in individuals of African, Hispanic, Indigenous American, and Asian descent compared to Caucasian populations3, 4.
2. Pathophysiology
The fundamental breakdown in systemic lupus erythematosus stems from defective clearance and phagocytosis of apoptotic cell debris, leading to the pathological accumulation of nuclear self-antigens such as double-stranded DNA (dsDNA) and small nuclear ribonucleoproteins1, 5. These unmasked self-antigens chronically stimulate innate immune pathways, notably activating plasmacytoid dendritic cells via Toll-like receptors (TLR7 and TLR9) to secrete copious quantities of type I interferons (IFN-alpha), which drive a systemic inflammatory cascade often referred to as the interferon signature5, 7. Consequently, aberrant antigen presentation and co-stimulation drive naive T cells into autoreactive effector phenotypes and promote T cell-dependent B cell maturation within secondary lymphoid organs5, 7. Clonal expansion of class-switched plasma cells yields high-affinity pathogenic autoantibodies (e.g., anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB) that bind circulating target antigens to form circulating immune complexes2, 5. These immune complexes deposit within the microvasculature, glomerular basement membranes, cutaneous dermal-epidermal junctions, and serosal surfaces, fixing complement proteins (triggering consumption and subsequent hypocomplementemia of C3 and C4) and recruiting neutrophils and macrophages that release pro-inflammatory cytokines, reactive oxygen species, and lysosomal enzymes, culminating in end-organ tissue destruction and fibrosis2, 5, 7.
3. Clinical Presentation & Classic Clinical Signs
History & Cardinal Symptoms: Patients commonly present with prolonged constitutional symptoms including debilitating fatigue, low-grade intermittent fevers, and involuntary weight loss2, 3. Early organ-specific complaints frequently involve symmetric arthralgias and arthritis, photosensitive skin eruptions, dry eyes and mouth, oral ulcerations, and Raynaud phenomenon2, 3.
Physical Examination & Named Clinical Signs:
Mucocutaneous Manifestations: Classic malar (butterfly) rash characterized by a fixed erythematous plaque distributed across the malar eminences and nasal bridge while characteristically sparing the nasolabial folds; discoid lupus plaques showing follicular plugging and scarring; painless, well-demarcated oral or nasal mucosal ulcerations; and non-scarring alopecia (lupus hair)1, 2.
Musculoskeletal Signs: Non-erosive, symmetrical polyarthritis predominantly affecting the small joints of the hands, wrists, and knees; uncommonly, chronic deforming reducible arthropathy (Jaccoud arthropathy) caused by periarticular soft tissue laxity rather than bone erosion1, 3.
Serosal Findings: Pleuritic chest pain and friction rubs indicative of pleuritis; sharp, positional retrosternal chest pain relieved by sitting forward, associated with pericarditis.
Renal & Vascular Findings: Peripheral dependent edema, foamy urine indicative of nephrotic-range proteinuria, new-onset hypertension (in lupus nephritis), and digital pallor followed by cyanosis and hyperemia upon cold exposure (secondary Raynaud phenomenon).
Antinuclear Antibody (ANA) screening via indirect immunofluorescence on HEp-2 cells showing a titer ≥1:80 (sensitivity >95%), paired with high-specificity confirmatory assays for Anti-dsDNA (correlating with lupus nephritis activity) and Anti-Smith (Anti-Sm) antibodies1, 2.
Laboratory Panel
Complete blood count demonstrating autoimmune cytopenias (leukopenia <4,000/µL, lymphopenia <1,000/µL, or Coombs-positive autoimmune hemolytic anemia with reticulocytosis and elevated indirect bilirubin; thrombocytopenia <100,000/µL); inflammatory markers showing elevated erythrocyte sedimentation rate (ESR) with paradoxically normal or minimally elevated C-reactive protein (CRP) unless secondary serositis or infection is present; depressed serum complement levels (C3, C4, and CH50) reflecting classical pathway consumption during active flares1, 2.
Imaging / Radiology (X-ray, US, CT, MRI)
Chest radiography demonstrating pleural effusions or atelectasis; high-resolution computed tomography (HRCT) showing interstitial lung disease or pulmonary vasculitis; echocardiography revealing pericardial effusion, Libman-Sacks non-bacterial verrucous endocarditis, or pulmonary arterial hypertension; Doppler ultrasonography evaluating deep venous thrombosis or renal artery perfusion. Renal ultrasound demonstrates normal-to-enlarged kidneys with increased cortical echogenicity in acute nephritis or small, scarred kidneys in end-stage lupus nephropathy.
ECG / Histopathology / Procedural
Electrocardiogram showing low voltage, diffuse ST-segment elevation (pericarditis), or conduction abnormalities. Renal biopsy remains the histopathological gold standard for classifying lupus nephritis (Classes I–VI according to ISN/RPS criteria) to guide aggressive immunosuppressive therapy. Skin punch biopsy of suspected cutaneous lesions demonstrates interface dermatitis with basal cell vacuolization and positive lupus band test (granular IgG and complement deposition at the dermal-epidermal junction).
5. Staging, Classification & Clinical Scoring Systems
Mandatory entry criterion: ANA titer ≥1:80 on HEp-2 cells. If positive, patient is evaluated across 7 clinical domains (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and 3 immunologic domains (antiphospholipid antibodies, complement proteins, SLE-specific autoantibodies). Each criterion is assigned weighted points ranging from 2 to 10; a cumulative score of ≥10 points classifies the patient as having SLE for research and diagnostic confirmation1, 6.
Class I: Minimal mesangial lupus nephritis. Class II: Mesangial proliferative lupus nephritis. Class III: Focal lupus nephritis (<50% of glomeruli involved; active/chronic, sclerosing). Class IV: Diffuse lupus nephritis (≥50% of glomeruli involved; segmental [IV-S] or global [IV-G]); requires aggressive induction immunosuppression. Class V: Membranous lupus nephritis (subepithelial immune complexes with heavy proteinuria). Class VI: Advanced sclerotic lupus nephritis (>90% globally sclerosed glomeruli; unresponsive to immunosuppression).
SLE Disease Activity Index (SLEDAI-2K)
Clinician-scored instrument capturing 24 clinical and laboratory descriptors over the preceding 10 days. Scores range from 0 to 105, where a score ≥6 indicates active disease requiring therapeutic modification or escalation.
6. Differential Diagnosis
Differential Condition
Distinguishing Clinical, Biochemical & Imaging Features
Rheumatoid Arthritis (RA)
Presents with symmetric, erosive polyarthritis involving the metacarpophalangeal and proximal interphalangeal joints with joint space narrowing and marginal erosions on radiographs. Typically positive for rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies; lacks hallmark malar rash, sterile nephritis, and anti-dsDNA antibodies.
Mixed Connective Tissue Disease (MCTD)
Overlapping clinical features of SLE, systemic sclerosis, and polymyositis. Characterized by high-titer speckled ANA and highly specific antibodies directed against U1 small nuclear ribonucleoprotein (anti-U1-RNP), coupled with a lower prevalence of severe renal disease.
Primary Antiphospholipid Syndrome (APS)
Features arterial or venous thrombosis and obstetric morbidity (recurrent fetal losses) in the persistent presence of lupus anticoagulant, anticardiolipin antibodies, or anti-beta-2-glycoprotein I antibodies. Can occur secondary to SLE or as a primary entity; distinguished by thrombotic events and microangiopathy without the broader immunologic triad of lupus.
Drug-Induced Lupus Erythematosus (DILE)
Triggered by medications (e.g., hydralazine, procainamide, isoniazid, minocycline). Presents with arthralgias, serositis, and fever, but renal and central nervous system involvement are exceedingly rare. Serologically characterized by positive anti-histone antibodies with negative anti-dsDNA and normal serum complement levels; symptoms resolve rapidly upon offending drug withdrawal.
7. Management & Treatment Protocol
Initial Stabilization & Resuscitation: Assess airway, breathing, and circulation in acute presentations involving severe flares (e.g., acute lupus pneumonitis, severe autoimmune hemolytic anemia, or central nervous system lupus). Correct electrolyte imbalances, manage hypertensive emergencies secondary to acute nephritis, and empirically cover suspected infections prior to initiating or escalating immunosuppression.
First-Line Medical / Pharmacological Therapy (with exact adult dosing):
Universal Baseline Therapy: Hydroxychloroquine administered at a weight-based dose of ≤5 mg/kg/day (maximum 400 mg orally once daily) for all diagnosed SLE patients unless contraindicated, as it reduces flare frequency, prevents organ damage, and improves long-term survival. Annual baseline ophthalmologic screening (spectral-domain OCT and visual fields) is mandatory to monitor for retinal toxicity.
Photoprotection & Topical Agents: Broad-spectrum sunscreens blocking ultraviolet A and B radiation, combined with topical potent or mid-potency corticosteroids (e.g., triamcinolone acetonide 0.1% cream) or topical calcineurin inhibitors (tacrolimus 0.1% ointment) for localized cutaneous lesions.
Systemic Corticosteroids: For acute flares or organ-threatening manifestations, oral prednisone initiated at 0.5–1 mg/kg/day with subsequent gradual tapering, or intravenous methylprednisolone pulse therapy (500–1,000 mg IV daily for 3 consecutive days) for severe life-threatening organ involvement (e.g., class III/IV lupus nephritis, severe cerebritis).
Targeted Immunosuppression for Organ-Threatening Disease (Lupus Nephritis / CNS Lupus):
Mycophenolate mofetil (MMF) induction dosing at 1,000 to 1,500 mg orally twice daily (or intravenous mycophenolate sodium equivalent) combined with low-dose glucocorticoids.
Alternatively, low-dose intravenous cyclophosphamide (Euro-Lupus regimen: 500 mg IV fixed dose every 2 weeks for 6 doses) or high-dose NIH cyclophosphamide regimen (0.5–1.0 g/m² body surface area monthly for 6 months).
Biological agents: Belimumab (human monoclonal antibody targeting B-lymphocyte stimulator [BLyS]) administered at 10 mg/kg IV every 4 weeks (or 200 mg subcutaneously weekly) added to standard therapy, or Rituximab (chimeric anti-CD20 monoclonal antibody) administered as 1,000 mg IV on days 1 and 15 for refractory disease.
Surgical / Interventional Indications: Renal biopsy performed percutaneously under ultrasound guidance to establish histological diagnosis and chronicity grading for lupus nephritis. Renal replacement therapy (hemodialysis or renal transplantation) indicated for end-stage renal disease secondary to irreversible class IV or VI lupus nephritis. Surgical intervention for catastrophic vascular thromboses or osteonecrosis of the femoral head (core decompression or total joint arthroplasty).
8. Complications & Prognosis
Key acute and chronic complications include lupus nephritis progressing to end-stage renal disease (affecting roughly 10% of patients with nephritis), accelerated premature cardiovascular disease (coronary artery disease, myocardial infarction, and stroke driven by chronic systemic inflammation and corticosteroid-induced dyslipidemia), opportunistic infections resulting from immunosuppressive therapy, antiphospholipid-mediated arterial and venous thrombosis, neuropsychiatric manifestations (seizures, psychosis, cognitive impairment), and refractory cytopenias1, 2, 3, 4, 7.
Although 10-year survival rates have improved dramatically over recent decades to exceed 85–90% due to earlier diagnosis and optimized immunosuppressive protocols, overall mortality remains two to three times higher than that of the general population, with infections and cardiovascular disease representing the leading causes of long-term mortality4, 7. Prognosis is heavily dictated by early recognition, strict adherence to hydroxychloroquine maintenance therapy, minimization of cumulative glucocorticoid exposure, and proactive multidisciplinary management of renal and vascular complications2, 3.
🎓 Board Exam Pearls & Clinical Pitfalls
Exam Pearl 1: Anti-dsDNA and anti-Smith (anti-Sm) antibodies are highly specific for SLE, whereas anti-dsDNA titers directly correlate with lupus nephritis disease activity and complement consumption.
Clinical Pitfall 2: Failing to maintain universal hydroxychloroquine therapy in all confirmed SLE patients substantially increases the risk of recurrent disease flares, irreversible organ damage, and long-term mortality.
Board Pearl 3: The 2019 EULAR/ACR criteria strictly require an entry screening ANA titer of at least 1:80 on HEp-2 cells; without this entry criterion, patients cannot be classified as having SLE regardless of cumulative clinical score.
📚 Verified PubMed & Guideline References (7) — click any reference to open the source
